Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors

Modern Pathology

Volumn 27, Issue 9, 2014, Pages 1193-1202

  Lezcano, Cecilia ^a,b   Lee, Chung Wei ^a,b   Larson, Allison R ^a,b   Menzies, Alexander M ^c,d   Kefford, Richard F ^c,d,e   Thompson, John F ^c,d,f,g   Mihm, Martin C ^a,b   Ogino, Shuji ^a,b,h,i   Long, Georgina V ^c,d,e   Scolyer, Richard A ^c,d,g   Murphy, George F ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f Mater Hospital   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Biomarker; HGF; Melanoma; RAF inhibitor

Indexed keywords

B RAF KINASE INHIBITOR; DABRAFENIB; SCATTER FACTOR; TUMOR MARKER; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MESSENGER RNA; OXIME; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFANT; MELANOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SKIN FIBROBLAST; TREATMENT RESPONSE; TUMOR BIOPSY; ANTAGONISTS AND INHIBITORS; CELL LINE; CYTOLOGY; FIBROBLAST; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SKIN; SKIN NEOPLASMS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE; FIBROBLASTS; GENE EXPRESSION; HEPATOCYTE GROWTH FACTOR; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; INDOLES; MELANOMA; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN; SKIN NEOPLASMS; SULFONAMIDES; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84925228592     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.226     Document Type: Article

References (49)

1. Poste G. Bring on the biomarkers. Nature 2011;469:156-157.
2. Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500-504.
3. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
4. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-714.
5. Sondak VK, Flaherty LE. Targeted therapies: improved outcomes for patients with metastatic melanoma. Nat Rev Clin Oncol 2011;8:513-515.
6. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011;9 (Suppl 5):S1-32.
7. Wilson TR, Fridlyand J, Yan Y, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012;487:505-509.
8. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
9. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379:1893-1901.
10. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-365.
11. Sullivan RJ, Flaherty K. MAP kinase signaling and inhibition in melanoma. Oncogene 2013;32:2373-2379.
12. Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013;31:1767-1774.
13. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-819.
14. Gupta PB, Kuperwasser C, Brunet JP, et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet 2005;37:1047-1054.
15. Girouard SD, Laga AC, Mihm MC, et al. SOX2 contributes to melanoma cell invasion. Lab Invest 2012;92:362-370.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
18. Kauma S, Hayes N, Weatherford S. The differential expression of hepatocyte growth factor and met in human placenta. J Clin Endocrinol Metab 1997;82:949-954.
19. Tamura M, Arakaki N, Tsubouchi H, et al. Enhancement of human hepatocyte growth factor production by interleukin-1 alpha and -1 beta and tumor necrosis factor-alpha by fibroblasts in culture. J Biol Chem 1993;268:8140-8145.
20. Kikuchi T, Abe T, Yaekashiwa M, et al. Secretory leukoprotease inhibitor augments hepatocyte growth factor production in human lung fibroblasts. Am J Respir Cell Mol Biol 2000;23:364-370.
21. Messadi DV, Pober JS, Fiers W, et al. Induction of an activation antigen on postcapillary venular endothelium in human skin organ culture. J Immunol 1987;139:1557-1562.
22. Fanelli D. Do pressures to publish increase scientists' bias? An empirical support from US States Data. PLoS One 2010;5:e10271.
23. Fanelli D. Negative results are disappearing from most disciplines and countries. Scientometrics 2012;90:891-904.
24. Schooler J. Unpublished results hide the decline effect. Nature 2011;470:437.
25. Marchio C, Dowsett M, Reis-Filho JS. Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box. BMC Med 2011;9:41.
26. Lim MD, Dickherber A, Compton CC. Before you analyze a human specimen, think quality, variability, and bias. Anal Chem 2011;83:8-13.
27. Lian CG, Xu Y, Ceol C, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012;150:1135-1146.
28. Menzies AM, Long GV, Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther 2012;6:391-405.
29. Hauschild A, Grob JJ, Demidov LV, et al. An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). J Clin Oncol 2013;31:abstract 9013.
30. Chapman PB, Hauschild A, Robert C, et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 2012;30:abstract 8502.
31. Matsuda-Hashii Y, Takai K, Ohta H, et al. Hepatocyte growth factor plays roles in the induction and autocrine maintenance of bone marrow stromal cell IL-11, SDF-1 alpha, and stem cell factor. Exp Hematol 2004;32:955-961.
32. Pons E, Uphoff CC, Drexler HG. Expression of hepatocyte growth factor and its receptor c-met in human leukemia-lymphoma cell lines. Leuk Res 1998;22:797-804.
33. Razzak M. From ASCO-targeted therapies: Anti-PD-1 approaches-important steps forward in metastatic melanoma. Nat Rev Clin Oncol 2013;10:365.
34. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-144.
35. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature 2008;451:345-349.
36. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-977.
37. Chartrain M, Riond J, Stennevin A, et al. Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. PLoS One 2012;7:e36762.
38. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013;19:1225-1231.
39. McDermott U, Pusapati RV, Christensen JG, et al. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res 2010;70:1625-1634.
40. McClaine RJ, Marshall AM, Wagh PK, et al. Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines. Neoplasia 2010;12:650-658.
41. Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68:9479-9487.
42. Yano S, Yamada T, Takeuchi S, et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 2011;6:2011-2017.
43. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043.
44. Sierra JR, Cepero V, Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 2010;9:75.
45. Jones HE, Goddard L, Gee JM, et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004;11:793-814.
46. Mahadevan D, Cooke L, Riley C, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 2007;26:3909-3919.
47. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008;118:2609-2619.
48. Jubb AM, Ribas A, Sosman JA, et al. Impact of MET expression on outcome in BRAF advanced melanoma. Histopathology 2013;63:351-361.
49. Chau CH, Rixe O, McLeod H, et al. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res 2008;14:5967-5976.